RxDoctor Payments Data

Lawrence Greenberg, MD

Family Medicine · San Pedro, CANPI 1043348436

Payments from drug & device makers

$1,353in general payments, 2019–2025

Across 15 payments — averaging $90.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$491
  • Novo Nordisk$295
  • Teva Pharmaceuticals USA, Inc.$130
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Lilly USA, LLC$125
  • Bayer$125
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$1,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,353 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$124,444
Medicare patients
226
Services billed
5,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$95,821
OzempicSemaglutide43$46,774
XifaxanRifaximin11$29,590
XareltoRivaroxaban51$27,372
RytaryCarbidopa/Levodopa30$22,965
JanuviaSitagliptin Phosphate53$22,955
SantylCollagenase Clostridium Hist.19$19,092
LinzessLinaclotide25$18,653
JanumetSitagliptin Phos/Metformin Hcl37$18,292
JardianceEmpagliflozin36$17,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,564
MyrbetriqMirabegron23$14,604
FarxigaDapagliflozin Propanediol13$13,292
EntrestoSacubitril/Valsartan53$12,133
Atorvastatin Calcium512$6,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$295$46,77443 claims
Johnson & JohnsonXarelto$24$27,37251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in San Pedro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →